PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Shorter fibrin clot lysis time linked to higher bleeding risk in atrial fibrillation patients on anticoagulants
Short clot breakdown time predicts higher bleeding risk
This RCT in 1,841 atrial fibrillation patients found that shorter pretreatment fibrin clot lysis time was associated with a significantly hi…
A simple blood test measuring how fast clots dissolve could help doctors spot patients at higher risk of bleeding before they even start tak…
Inflammatory and cardiac markers linked to VTE and bleeding risks in cancer patients on apixaban
</think>
A post hoc analysis of an RCT in 574 ambulatory cancer patients with a Khorana score ≥2 found that elevated baseline growth differentiation …
New Blood Tests May Predict Clot and Bleed Risks in
Network meta-analysis compares prophylactic anticoagulants for central venous catheter-related thrombosis in cancer patients.
Cancer Patients May Avoid Clots With Safer Blood Thinner
This network meta-analysis synthesizes data from 19 clinical studies regarding prophylactic anticoagulation in cancer patients with central …
A new analysis shows one specific blood thinner may protect cancer patients from dangerous clots with fewer side effects.
Apixaban Plasma Levels Elevated in Medicare Patients Taking CYP3A4 and P-gp Inhibitors
Higher Drug Levels Mean More Bleeding Risk
This pilot cohort study evaluated 35 Medicare patients with atrial fibrillation receiving apixaban 5mg BID. Apixaban plasma concentrations w…
Taking common heart rhythm drugs with apixaban raises blood levels and increases the risk of serious bleeding that can lead to hospitalizati…
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis
Your DNA May Explain Why Blood Thinners Work Differently for You
A meta-analysis of 39 studies involving 13,300 patients found that genetic polymorphisms (e.g., CES1, ABCB1) are associated with pharmacokin…
Tiny DNA differences may explain why the same blood thinner protects one person but causes bleeding in another.
Apixaban alters hemostatic biomarkers in children with heart disease compared to standard care.
New Blood Test Shows Apixaban Works Safely in Kids
This exploratory biomarker substudy of an RCT in children over one year with heart disease assessed apixaban versus standard care (vitamin K…
A new blood test confirms apixaban works safely for children with heart disease, offering a simpler alternative to painful injections and fr…
DOACs show varied efficacy and safety profiles versus VKAs in atrial fibrillation patients with fall risk
Study compares blood thinners for atrial fibrillation patients with fall risk
A Bayesian network meta-analysis of 10 studies (5 RCTs, 5 observational) in AF patients with fall history/risk found apixaban ranked highest…
For atrial fibrillation patients at risk of falling, apixaban best prevents strokes while edoxaban best lowers major bleeding risks compared…